SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in develo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of translational medicine 2020-06, Vol.18 (1), p.222-3, Article 222
Hauptverfasser:	Salvatori, Giovanni, Luberto, Laura, Maffei, Mariano, Aurisicchio, Luigi, Roscilli, Giuseppe, Palombo, Fabio, Marra, Emanuele
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies Antibodies, Viral - adverse effects Antibodies, Viral - biosynthesis Antibody-Dependent Enhancement - immunology B cells Betacoronavirus - genetics Betacoronavirus - immunology Betacoronavirus - pathogenicity Coronavirus Infections - epidemiology Coronavirus Infections - genetics Coronavirus Infections - immunology Coronavirus Infections - prevention & control Coronaviruses COVID-19 COVID-19 Vaccines Deoxyribonucleic acid Development and progression DNA Drug therapy Enzymes Epidemics Glycoproteins Health aspects Humans Immunotherapy Infections Middle East respiratory syndrome Pandemics Pandemics - prevention & control Pneumonia, Viral - epidemiology Pneumonia, Viral - immunology Pneumonia, Viral - prevention & control Proteins SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - chemistry Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology SPIKE protein Translational Medical Research Vaccine Vaccines Viral Vaccines - adverse effects Viral Vaccines - genetics Viral Vaccines - immunology Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.
ISSN:	1479-5876 1479-5876
DOI:	10.1186/s12967-020-02392-y